embrel.com) it was deemed safe to use in patients who had Hepatitis C Lab tests were ordered and conducted on the 60-year-old patients liver, and the results indicated normal enzyme production in the liver. In August 2004, the patient was started on Enbrel 50 MG twice a week, and some immediate improvement was noted; but after 18 weeks, the patient, who was inconsistent in making appointments, showed a worsened psoriasis condition. The dosage was cut to 50 MG once a week, and patient was urged to visit his liver doctor to have PCR for his Hepatitis C titers (concentration), to repeat CBC and Liver Function Test (LFT) titers (which was normal in Aug. 2002).

A mild elevation of LFTs was discovered, so the patient was worked up further with ultrasound and a liver biopsy. The patient was then started in IFN treatment and Enbrel was discontinued. By June, 2006, the patients LFT had returned to normal.

The bottom line with reference to this case is that this office believes Enbrel did indeed play a role in the reactivation of the patients Hepatitis C, which suggests that Enbrel does not meet the claims of safety in the manufacturers literature.

Works Cited

Enbrel. “Important Product Information: What do I need to know about Enbrel?” Retrieved.